Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PPOS starting day 5 vs conventional PPOS from stimulation start in oocyte donors
2022-002678-10Phase 4Active
- Sponsor
- Ginefiv
- Start
- Jan 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of medroxyprogesterone acetate (2 arms), sponsored by Ginefiv. Primary endpoint: Number of MII oocytes. Started Jan 2023; status: active.
02
Drugs
medroxyprogesterone acetate
Beyond the preview
Go deeper on 2022-002678-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002678-10.